March 30, 2026
Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, discuss how results from FLAURA2 (NCT04035486) and MARIPOSA (NCT04487080) have introduced meaningful overall survival benefits with intensified approaches. They consider patient age, comorbidities, renal function, lifestyle factors, and treatment logistics. They also discuss the importance of disease burden and central nervous system involvement, while acknowledging the potential risk of overtreatment and the need to balance efficacy, toxicity, and long-term sequencing flexibility.
Related Posts
Rethinking High-Risk EGFR-Mutant NSCLC
Integrating ctDNA Into Frontline Decision-Making in EGFR-Mutant NSCLC
Sequencing Strategies After Frontline Intensification in EGFR-Mutant NSCLC
The Emerging Role of ADCs in EGFR-Mutant NSCLC
Future Directions: Toward Personalized EGFR Therapy in NSCLC
